Novelion CEO Steps Down From Novo Nordisk A/S Board Due To NASH Conflict
Change in composition of the Board of Directors of Novo Nordisk A/S
Bagsværd, Denmark, 16 May 2017 - Novo Nordisk today announced that Mary Szela steps down from Novo Nordisk's board of directors with immediate effect. The decision follows changed strategic focus for Novelion Therapeutics, a US-based rare disease company, where Ms Szela serves as CEO, which could lead to a potential conflict of interest.
"I acknowledge and support Ms Szela's decision to step down from the Board of Directors and I would like to thank Ms Szela for her valuable contribution since joining in March 2015," said Göran Ando, chairman of the Board of Directors at Novo Nordisk.
Further information
| Media: | ||
| Anne Margrethe Hauge | +45 3079 3450 | amhg@novonordisk.com |
| Ken Inchausti (US) | +1 609 786 8316 | kiau@novonordisk.com |
| Investors: | ||
| Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
| Hanna Ögren | +45 3079 8519 | haoe@novonordisk.com |
| Anders Mikkelsen | +45 3079 4461 | armk@novonordisk.com |
| Kasper Veje (US) | +1 609 235 8567 | kpvj@novonordisk.com |
Company announcement No 37 / 2017
Attachments:http://www.globenewswire.com/NewsRoom/AttachmentNg/d6a738ba-d5dd-4997-a3e4-d61448df4757